Oncotype DX-guided vs physician-directed chemotherapy and survival in HR+/HER2- breast cancer.
Journal: Breast (Edinburgh, Scotland)
•
Abstract
Abstract text is not embedded in this discovery record. Please consult the full-text publication via the source link on the right.
Subjects & Keywords
How to Cite this Article
Li J, Han X, Zhuang Y, et al. (2026). "Oncotype DX-guided vs physician-directed chemotherapy and survival in HR+/HER2- breast cancer.". Breast (Edinburgh, Scotland). https://doi.org/10.1016/j.breast.2026.104906